新的评分系统,用于排名血造干细胞移植的血造干细胞移植
Lee Ann Baxter-Lowe1, Tao Wang2,3, Michelle Kuxhausen4
1University of Southern California and Children's Hospital Los Angeles, Los Angeles, California, USA.
Clinical transplantation
|November 8, 2024
概括
在血造干细胞移植 (HSCT) 中的人类白细胞抗原 (HLA) 不匹配的新评分系统没有显著预测结果. 然而,没有结差异的HLA不匹配 (分数=0) 可能表明更好的移植相关死亡率,扩大了允许的供体选择.
科学领域:
- 免疫遗传学 免疫遗传学
- 移植免疫学 移植免疫学
- 血液学 血液学 血液学
背景情况:
- 造血干细胞移植 (HSCT) 依赖于人类白细胞抗原 (HLA) 匹配,以获得最佳的结果.
- 由于缺乏普遍接受的指导方针来排名7/8 HLA匹配的非相关捐赠者,当 HLA匹配的捐赠者无法获得时,这就带来了挑战.
- 研究了一种新的评分系统,以对与无关的捐赠者HSCT中的HLA不匹配进行排名.
研究的目的:
- 研究一种新的评分系统,用于在7/8 HLA匹配的无关捐赠体HSCT中排名单个HLA I类不匹配.
- 评估这种评分系统与整体存活率和急性移植对宿主疾病 (GVHD) 的关联.
主要方法:
- 高分辨率的HLA类型识别用于识别HLA抗原识别域中的氨基酸不匹配.
- 基于影响结的物理化学性质,T细胞受体对接以及HLA结构/功能的不匹配的评分.
- 对2319名白血病/骨髓质疏松症候群患者的队列进行分析,这些患者接受了第一个无关联的供体HSCT.
主要成果:
- 新的评分系统与移植结果 (整体存活率,急性GVHD) 没有显著的相关性.
- 分数为0 (没有结变化) 与较低的移植相关死亡率 (TRM) 相关 (p=0.019).
- 与分数 = 0 的HLA不匹配包括HLA-C*03:03/03:04和其他特定不匹配,此前被认为是允许的.
结论:
- 没有改变结的HLA不匹配 (分数 = 0) 可能代表允许的不匹配,可能会扩大捐赠池.
- 需要进一步的研究来验证这些发现,并探索用于HLA不匹配供体选择的替代评分系统.
更多相关视频
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.7K
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
7.1K
相关概念视频
01:22Bone Marrow Sampling and Transplants
286
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
286
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:21Hematopoiesis
5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K